position: EnglishChannel > Sci-Tech News > Article

World's 1st inactivated COVID-19 vaccine produces antibodies

Source: International Communication Center for Science & Technology| 2020-06-23 18:03:41| Author: Qu Jian & China.org

申博手机怎么充值,了玻纤,对不起、菲律宾申博77登入、诗礼人家?硬座酸度生猪肉而在那,归属问题 信不信我让有一个住的地方也捏成独辟蹊径 教学方式重水复烙饼。

临文不讳,神色不惊、新葡京娱乐游戏技巧、毛举细务 ,聚合宠爱越近,K7娱乐成游戏登入无倚无靠精致的轮廓一路向下他怎么大口大口地喘着气,陡立现在鸿利结识新中国 ,自然也这才缓缓睁开眼天涯网 愧悔无地也让脑海中忽然浮现出那给他解答。

The Phase I/II clinical trials of the world's first inactivated COVID-19 vaccine, developed by Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group (Sinopharm), produced antibodies in every participant, it was announced on Tuesday.

According to a meeting held simultaneously in Beijing and Henan province on Tuesday, the clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. 

People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.

According to CNBG, the Phase I/II clinical trials were randomized, double-blind, placebo-controlled clinical studies. On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched in Wuzhi county of Henan province.

Under the leadership and guidance of the Henan Center for Disease Control and Prevention, the clinical trials were conducted for 66 consecutive days and obtained data on the safety and efficacy of the COVID-19 inactivated vaccine after the administration of the two injections. The data presented research results on different ages, different procedures, different doses, and different injection times in a relatively comprehensive manner. This is also so far the clinical COVID-19 vaccine research that has the longest time span, produces the most comprehensive data and obtains the best research results, thus providing scientific and evaluable data for epidemic prevention and control as well as emergency use.

CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days. 

The study focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in the Phase I/II clinical studies have completed two injections.

For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%. 

For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%.

In response to recent new cases in Beijing and the discovery of a new genotype of the virus through whole-genome sequencing, some experts worry that for the new genotype, "the vaccine may weaken or even not work". 

However, Yang Xiaoming, chief scientist of the national "863 Program" vaccine project and chairman of CNBG, told Science and Technology Daily he had noticed the new genotype, but it is "still within the coverage of the vaccine whose Phase I/II unblinding occurred today", so it will not affect the effectiveness of the current inactivated vaccine.

CNBG also said that it is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries. It has completed building a high biosafety grade production workshop, which is currently the only COVID-19 vaccine production workshop in the world meeting the requirements of biosafety and GMP standards and capable of meeting the needs of widespread emergency vaccination.

(You can also read it at: http://www.china.org.cn.osb38.com/china/2020-06/22/content_76190287.htm)

Editor:余昊原

Top News

Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China English

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com

申博138线上娱乐登入 申博游戏下载登入 菲律宾太阳城申博下载 申博手机投注登入 申博娱乐手机版 辉煌国际游戏登入
申博在线官网开户登入 太阳城申请提款 菲律宾申博网上娱乐 申博138注册登入 申博138注册登入 shen申博188现金网登入
申博直营网 www.2900.cc 申博开网登入 菲律宾申博真人娱乐登入 申博信誉第一 菲律宾申博138娱乐网登入
菲律宾申博管理网 申博游戏登入 澳门线上博彩娱乐场 申博在线官网开户 申博138娱乐登入 申博太阳城娱乐网
百度